|
시장보고서
상품코드
1890923
괴사성근막염 시장 : 유형별, 치료법별, 투여 경로별, 해부학적 부위별, 최종사용자별, 유통경로별, 리스크 요인별, 연령층별, 지역별Necrotizing Fasciitis Market, By Type, By Treatment Modality, By Route of Administration, By Anatomical Location, By End User, By Distribution Channel, By Risk-Factor, By Age Group, By Geography |
||||||
괴사성근막염 시장은 2025년에 12억 1,000만 달러로 추정되며, 2032년까지 21억 4,000만 달러에 달할 것으로 예측됩니다. 2025-2032년의 CAGR은 8.5%로 전망되고 있습니다.
| 리포트 내용 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2024년 | 2025년 시장 규모 : | 12억 1,000만 달러 |
| 과거 데이터 대상 기간 : | 2020-2024년 | 예측 기간 : | 2025-2032년 |
| 예측 기간인 2025-2032년의 CAGR : | 8.50% | 2032년 예측 : | 21억 4,000만 달러 |
괴사성 근막염은 근막과 주변 조직의 광범위한 괴사를 특징으로 하는 가장 심각하고 빠르게 진행되는 연조직 감염 중 하나이며, 치명적인 결과를 예방하기 위해 즉각적인 의료적 개입이 필요합니다.
드물지만 심각한 세균 감염으로 흔히 '육식성 질환'이라고도 불리는 이 질환은 피부의 심부 및 피하 조직에 영향을 미치는 희귀한 질환입니다. 적극적인 치료 프로토콜을 시행해도 사망률은 20%에서 40%에 달할 전망입니다. 세계 괴사성 근막염 시장은 생명을 위협하는 이 질환과 싸우기 위해 고안된 진단 툴, 치료 중재, 수술 툴 및 지지요법 기술의 종합적인 생태계를 포함하고 있습니다.
시장의 발전은 의료진의 인식 개선, 신속 진단 기술의 발전, 표적 항균 요법의 개발로 인해 촉진되고 있습니다. 주요 시장 부문에는 영상 진단 기술 및 검사 키트와 같은 진단 솔루션, 광범위 항생제 및 면역글로불린 치료제와 같은 치료 제품, 상처 세척에 필수적인 수술 툴 등이 포함됩니다.
또한 심각한 연조직 감염의 위험을 증가시키는 당뇨병 및 면역 결핍 상태의 유병률 증가, 개발도상국의 의료비 지출 확대, 환자 결과 개선 및 치료 기간 단축에 초점을 맞춘 지속적인 연구 활동도 시장 상황에 영향을 미치고 있습니다.
시장 역학
세계 괴사성 근막염 시장은 주로 몇 가지 강력한 요인에 의해 주도되고 있으며, 이러한 요인들이 결합되어 시장 확대와 혁신을 촉진하고 있습니다. 전 세계에서 당뇨병 및 기타 면역 결핍 질환의 발생률이 증가함에 따라 심각한 연조직 감염의 위험이 크게 증가하고 있으며, 전문적인 치료 개입이 필요한 환자군이 확대되고 있습니다.
헬스케어에 대한 인식이 높아지고 진단 능력이 향상됨에 따라 조기 발견 및 조기 개입이 가능해져 환자의 생존율과 회복 결과에 결정적인 영향을 미치고 있습니다. 현장 검사 장비와 첨단 영상 진단 장비를 포함한 신속한 진단 툴의 기술 발전은 괴사성 근막염의 조기 발견을 촉진하고, 혁신적인 진단 솔루션에 대한 시장 수요를 견인하고 있습니다.
또한 새로운 항균제 및 병용요법의 개발은 항생제 내성에 대한 우려를 해소하는 한편, 신흥 경제국의 의료비 지출 증가는 시장 접근성 확대에 기여하고 있습니다. 그러나 이 시장은 심각한 제약에 직면해 있습니다. 질환의 희귀성으로 인해 대규모 임상시험이 제한되어 연구 진전이 지연되고, 응급 치료 프로토콜과 장기 입원에 따른 고비용이 환자와 의료 시스템에 경제적 장벽으로 작용하고 있습니다.
진단의 복잡성은 종종 치료 시작을 지연시키고, 환자의 예후가 나빠지거나 의료 서비스 프로바이더에 대한 소송의 위험으로 이어집니다. 또한 1차 진료 의사 및 응급실 직원들의 인식 부족이 오진 및 인식 지연의 원인이 될 수 있습니다. 이러한 과제에도 불구하고 신속 진단 플랫폼 개발, 표적 치료 솔루션 창출, 원격 진료 및 진단을 위한 원격의료 기능 확대, 전문 치료 센터 설립 등의 분야에는 큰 기회가 존재합니다.
본 조사의 주요 특징
- 이 보고서는 괴사성 근막염 세계 시장에 대한 상세한 분석을 제공하며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모(10억 달러)와 예측 기간(2025-2032년)의 CAGR(%)을 제시합니다.
- 또한 다양한 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명할 것입니다.
- 이 보고서는 시장 성장 촉진요인, 제약요인, 기회, 신제품 출시 또는 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략에 대한 중요 인사이트를 제공합니다.
- 이 보고서에서는 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등 다양한 매개 변수를 기반으로 세계 괴사성 근막염 시장의 주요 기업 개요을 제공합니다.
- 이 보고서는 마케팅 담당자 및 기업 경영진이 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있도록 돕습니다.
- 이 세계 괴사성 근막염 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해 관계자를 대상으로 합니다.
- 이해관계자들은 세계 괴사성 근막염 시장 분석에 사용된 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
- 조사 목적
- 전제조건
- 약어
제2장 시장 범위
- 리포트 개요
- 시장 정의와 범위
- 개요
제3장 시장 역학, 규제 및 동향 분석
- 시장 역학
- 촉진요인
- 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 환경
- 제품 발매·승인
- PEST 분석
- Porter의 산업 분석
- 합병·인수의 동향
- 업계 동향
제4장 세계의 괴사성근막염 시장 : 유형별, 2020-2032년
- 다균성(유형 I)
- 단일 미생물(유형 II)
- 클로스트리듐/가스 회저(III형)
- 기타(예 : 진균성 괴사성 감염증, 비정형 병원체)
제5장 세계의 괴사성근막염 시장 : 치료법별, 2020-2032년
- 외과적/개입적 치료(예 : 창면 절제술, 절단술)
- 항생제/항균 요법
- 보조 요법(예 : 고기압 산소 요법, 창상관리 디바이스)
- 기타(지지요법)
제6장 세계의 괴사성근막염 시장 : 투여 경로별, 2020-2032년
- 비경구
- 경구
제7장 세계의 괴사성근막염 시장 : 해부학적 부위별, 2020-2032년
- 상지
- 하지
- 회음부 및 생식기(Fournier's Gangrene)
- 두경부
- 체간 및 복벽
제8장 세계의 괴사성근막염 시장 : 최종사용자별, 2020-2032년
- 병원 및 진료소
- 외래 수술 센터
- 재활 센터
- 진단 센터
- 학술·연구기관
- 재택 헬스케어
제9장 세계의 괴사성근막염 시장 : 유통경로별, 2020-2032년
- 병원 약국
- 소매 약국
- 온라인 약국/전자 약국
제10장 세계의 괴사성근막염 시장 : 리스크 요인별, 2020-2032년
- 당뇨병
- 비만
- 면역 부전/종양 환자
- 말초혈관 질환/만성 신장병
- 정맥내 약물 사용자/알코올 중독
제11장 세계의 괴사성근막염 시장 : 연령층별, 2020-2032년
- 유아 및 소아(18세 미만)
- 성인(18-64세)
- 고령자(65세 이상)
제12장 세계의 괴사성근막염 시장 : 지역별, 2020-2032년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카 국가
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동 국가
- 아프리카
- 남아프리카공화국
- 북아프리카
- 중앙아프리카
제13장 경쟁 구도
- Pfizer Inc
- Merck and Co Inc
- GlaxoSmithKline plc
- Novartis AG
- Bayer AG
- Abbott Laboratories
- Baxter International Inc
- Melinta Therapeutics LLC
- Atox Bio Inc
- Wound Care Technologies Inc
- ConvaTec Group Plc
- Smith and Nephew plc
- Molnlycke Health Care AB
- 3M Company
- Becton Dickinson and Company
제14장 애널리스트의 권장사항
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map
제15장 참고 문헌과 조사 방법
- 참고 문헌
- 조사 방법
- 출판사 소개
Necrotizing Fasciitis Market is estimated to be valued at USD 1.21 Bn in 2025 and is expected to reach USD 2.14 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.5% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 1.21 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 8.50% | 2032 Value Projection: | USD 2.14 Bn |
Necrotizing fasciitis represents one of the most critical and rapidly progressive soft tissue infections, characterized by extensive necrosis of the fascia and surrounding tissues, demanding immediate medical intervention to prevent fatal outcomes.
This rare but severe bacterial infection, often termed as flesh-eating disease, affects the deep layers of skin and subcutaneous tissues, with mortality rates ranging from 20% to 40% despite aggressive treatment protocols. The global necrotizing fasciitis market encompasses a comprehensive ecosystem of diagnostic tools, therapeutic interventions, surgical instruments, and supportive care technologies designed to combat this life-threatening condition.
The market's evolution is driven by increasing awareness among healthcare professionals, advancements in rapid diagnostic techniques, and the development of targeted antimicrobial therapies. Key market segments include diagnostic solutions such as imaging technologies and laboratory testing kits, therapeutic products including broad-spectrum antibiotics and immunoglobulin treatments, and surgical instruments essential for debridement procedures.
The market landscape is further influenced by the growing prevalence of diabetes and immunocompromised conditions that predispose patients to severe soft tissue infections, alongside rising healthcare expenditure in developing economies and continuous research initiatives focused on improving patient outcomes and reducing treatment timelines.
Market Dynamics
The global necrotizing fasciitis market is primarily driven by several compelling factors that collectively fuel market expansion and innovation. The increasing incidence of diabetes mellitus and other immunocompromising conditions worldwide significantly elevates the risk of severe soft tissue infections, creating a larger patient population requiring specialized treatment interventions.
Rising healthcare awareness and improved diagnostic capabilities enable earlier detection and intervention, which is crucial for patient survival and recovery outcomes. Technological advancements in rapid diagnostic tools, including point-of-care testing devices and advanced imaging modalities, facilitate quicker identification of necrotizing fasciitis, thereby driving market demand for innovative diagnostic solutions.
Additionally, the development of novel antimicrobial agents and combination therapies addresses the growing concern of antibiotic resistance, while increased healthcare spending in emerging economies expands market accessibility. However, the market faces significant restraints including the rarity of the condition, which limits large-scale clinical trials and slows research progress, alongside the high costs associated with emergency treatment protocols and extended hospital stays that create financial barriers for patients and healthcare systems.
The complexity of diagnosis often leads to delayed treatment initiation, resulting in poor patient outcomes and potential litigation concerns for healthcare providers. Furthermore, limited awareness among primary care physicians and emergency department staff can contribute to misdiagnosis or delayed recognition. Despite these challenges, substantial opportunities exist in developing rapid diagnostic platforms, creating targeted therapeutic solutions, expanding telemedicine capabilities for remote consultation and diagnosis, and establishing specialized treatment centers.
Key Features of the Study
- This report provides in-depth analysis of the global necrotizing fasciitis market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global necrotizing fasciitis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc, Merck and Co Inc, GlaxoSmithKline plc, Novartis AG, Bayer AG, Abbott Laboratories, Baxter International Inc, Melinta Therapeutics LLC, Atox Bio Inc, Wound Care Technologies Inc, ConvaTec Group Plc, Smith and Nephew plc, Molnlycke Health Care AB, 3M Company, and Becton Dickinson and Company
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global necrotizing fasciitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global necrotizing fasciitis market
Market Segmentation
- Type Insights (Revenue, USD Bn, 2020 - 2032)
- Polymicrobial (Type I)
- Monomicrobial (Type II)
- Clostridial / Gas gangrene (Type III)
- Others (e.g., Fungal necrotizing infections, atypical pathogens)
- Treatment Modality Insights (Revenue, USD Bn, 2020 - 2032)
- Surgical/interventional (e.g., debridement, amputation)
- Antibiotic/antimicrobial therapy
- Adjunctive therapies (e.g., hyperbaric oxygen, wound-care devices)
- Other (Supportive care)
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Parenteral
- Oral
- Anatomical Location Insights (Revenue, USD Bn, 2020 - 2032)
- Upper Extremities
- Lower Extremities
- Perineal and Genital (Fournier's Gangrene)
- Head and Neck
- Torso and Abdominal Wall
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals and Clinics
- Ambulatory Surgical Centers
- Rehabilitation Centers
- Diagnostic Centers
- Academic and Research Institutes
- Home Healthcare
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital pharmacies
- Retail pharmacies
- Online/epharmacy
- Risk-factor Insights (Revenue, USD Bn, 2020 - 2032)
- Diabetes mellitus
- Obesity
- Immunocompromised/oncology patients
- Peripheral vascular disease/chronic kidney disease
- Intravenous drug users/alcoholism
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Infants and children (< 18 years)
- Adults (18-64 years)
- Seniors (65+ years)
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc
- Merck and Co Inc
- GlaxoSmithKline plc
- Novartis AG
- Bayer AG
- Abbott Laboratories
- Baxter International Inc
- Melinta Therapeutics LLC
- Atox Bio Inc
- Wound Care Technologies Inc
- ConvaTec Group Plc
- Smith and Nephew plc
- Molnlycke Health Care AB
- 3M Company
- Becton Dickinson and Company
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Necrotizing Fasciitis Market, By Type
- Global Necrotizing Fasciitis Market, By Treatment Modality
- Global Necrotizing Fasciitis Market, By Route of Administration
- Global Necrotizing Fasciitis Market, By Anatomical Location
- Global Necrotizing Fasciitis Market, By End User
- Global Necrotizing Fasciitis Market, By Distribution Channel
- Global Necrotizing Fasciitis Market, By Risk-Factor
- Global Necrotizing Fasciitis Market, By Age Group
- Global Necrotizing Fasciitis Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Necrotizing Fasciitis Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Polymicrobial (Type I)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Monomicrobial (Type II)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Clostridial / Gas gangrene (Type III)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (e.g., Fungal necrotizing infections, atypical pathogens)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Necrotizing Fasciitis Market, By Treatment Modality, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Surgical/interventional (e.g., debridement, amputation)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Antibiotic/antimicrobial therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Adjunctive therapies (e.g., hyperbaric oxygen, wound-care devices)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other (Supportive care)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Necrotizing Fasciitis Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Necrotizing Fasciitis Market, By Anatomical Location, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Upper Extremities
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Lower Extremities
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Perineal and Genital (Fournier's Gangrene)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Head and Neck
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Torso and Abdominal Wall
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Necrotizing Fasciitis Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Rehabilitation Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Diagnostic Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Academic and Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Home Healthcare
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Necrotizing Fasciitis Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online/epharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Necrotizing Fasciitis Market, By Risk-Factor, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Diabetes mellitus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Obesity
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Immunocompromised/oncology patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Peripheral vascular disease/chronic kidney disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intravenous drug users/alcoholism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Necrotizing Fasciitis Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Infants and children (< 18 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Adults (18-64 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Seniors (65+ years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
12. Global Necrotizing Fasciitis Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Anatomical Location, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Risk-Factor, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Anatomical Location, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Risk-Factor, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Anatomical Location, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Risk-Factor, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Anatomical Location, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Risk-Factor, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Anatomical Location, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Risk-Factor, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Anatomical Location, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Risk-Factor, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
13. Competitive Landscape
- Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck and Co Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Baxter International Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Melinta Therapeutics LLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Atox Bio Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Wound Care Technologies Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- ConvaTec Group Plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Smith and Nephew plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Molnlycke Health Care AB
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- 3M Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Becton Dickinson and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
14. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
15. References and Research Methodology
- References
- Research Methodology
- About us
